Patents by Inventor Siv Ahrné
Siv Ahrné has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220305064Abstract: The invention relates to at least one strain of Lactobacillus for use in a method of reducing and/or preventing at least one deleterious effect of acute psychosocial stress in a human, wherein the method comprises treatment by administration of an effective dose of the at least one strain of. The at least one deleterious effect may be an elevated level of soluble fractalkine and may be in combination with at least one further deleterious effect of acute psychosocial stress.Type: ApplicationFiled: June 5, 2020Publication date: September 29, 2022Inventors: Magnus Hillman, Siv Ahrné, Gunilla Önning
-
Patent number: 10893695Abstract: The present invention relates to a novel bacterial strain, L. plantarum GOS 42 (DSM 32131), isolated preparations and compositions thereof; and their use in medicine, especially in the treatment and/or prevention of inflammation.Type: GrantFiled: July 13, 2018Date of Patent: January 19, 2021Assignee: Probi ABInventors: Jörg Thilo Fischer, Marcus Rudolf Götz, Göran Molin, Siv Ahrne
-
Publication number: 20190037902Abstract: The present invention relates to a novel bacterial strain, L. plantarum GOS 42 (DSM 32131), isolated preparations and compositions thereof; and their use in medicine, especially in the treatment and/or prevention of inflammation.Type: ApplicationFiled: July 13, 2018Publication date: February 7, 2019Inventors: Jörg Thilo Fischer, Marcus Rudolf Götz, Göran Molin, Siv Ahrne
-
Patent number: 8586026Abstract: Use of one strain of Lactobacillus plantarum for the manufacture of a composition for increasing the diversity of the gastrointestinal tract by administration of said strain to an individual with a view to producing an increased diversity index compared to placebo is disclosed, as well as use of one strain of Lactobacillus plantarum for the manufacture of a composition for prophylactic treatment of a healthy individual against developing a low bacterial diversity (LBD); of an individual having LBD against developing one or more physiologically disturbed conditions, large intestine bacterial overgrowth (LIBO) or small intestine bacterial overgrowth (SIBO); and of an individual having LIBO or SIBO against developing one or more physiologically disturbed conditions, and a method for increasing said diversity.Type: GrantFiled: February 29, 2008Date of Patent: November 19, 2013Assignee: Probi ABInventors: Goran Molin, Siv Ahrne, Caroline Karlsson, Bengt Jeppsson
-
Patent number: 7947482Abstract: The invention refers to new strains of Bifidobacterium, especially of the species Bifidobacterium infantis, having the ability to survive in the intestinal tract and to produce glutamine and optionally arginine in vivo, as well as to compositions comprising said strains.Type: GrantFiled: January 27, 2004Date of Patent: May 24, 2011Assignee: Probi ABInventors: Goran Molin, Siv Ahrne, Bengt Jeppsson
-
Patent number: 7807440Abstract: The present invention relates to a probiotic bacterial strain belonging to the genus Lactobacillus having the ability to colonize the human vagina, or a variant thereof. More specifically the probiotic bacterial strain belongs to a species chosen from the group comprising Lactobacillus plantarum, Lactobacillus crispatus, and Lactobacillus gasseri. Further it relates to its use as a medicament, a composition comprising the strain, the composition, e.g., being a food product or a pharmaceutical composition, a hygiene product, a biological pure culture of the strain, and a novel food.Type: GrantFiled: October 5, 2005Date of Patent: October 5, 2010Assignee: Probi ABInventors: Göran Molin, Siv Ahrné, Bengt Jeppsson, Alejandra Vasquez, Anna Berggren
-
Publication number: 20100143463Abstract: Use of one strain of Lactobacillus plantarum for the manufacture of a composition for increasing the diversity of the gastrointestinal tract by administration of said strain to an individual with a view to producing an increased diversity index compared to placebo is disclosed, as well as use of one strain of Lactobacillus plantarum for the manufacture of a composition for prophylactic treatment of a healthy individual against developing a low bacterial diversity (LBD); of an individual having LBD against developing one or more physiologically disturbed conditions, large intestine bacterial overgrowth (LIBO) or small intestine bacterial overgrowth (SIBO); and of an individual having LIBO or SIBO against developing one or more physiologically disturbed conditions, and a method for increasing said diversity.Type: ApplicationFiled: February 29, 2008Publication date: June 10, 2010Applicant: PROBI ABInventors: Goran Molin, Siv Ahrne, Caroline Karlsson, Bengt Jeppsson
-
Patent number: 7507572Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.Type: GrantFiled: April 2, 2004Date of Patent: March 24, 2009Assignee: Probi ABInventors: Göran Molin, Siv Ahrné, Bengt Jeppsson
-
Publication number: 20080268006Abstract: The present invention relates to a probiotic bacterial strain belonging to the genus Lactobacillus having the ability to colonize the human vagina, or a variant thereof. More specifically the probiotic bacterial strain belongs to a species chosen from the group comprising Lactobacillus plantarum, Lactobacillus crispatus, and Lactobacillus gasseri. Further it relates to its use as a medicament, a composition comprising the strain, the composition, e.g., being a food product or a pharmaceutical composition, a hygiene product, a biological pure culture of the strain, and a novel food.Type: ApplicationFiled: October 5, 2005Publication date: October 30, 2008Applicant: PROBI ABInventors: Goran Molin, Siv Ahrne, Bengt Jeppsson, Alejandra Vasquez, Anna Berggren
-
Publication number: 20060269533Abstract: The invention refers to new strains of Bifidobacterium, especially of the species Bifidobacterium infantis, having the ability to survive in the intestinal tract and to produce glutamine and optionally arginine in vivo, as well as to compositions comprising said strains.Type: ApplicationFiled: January 27, 2004Publication date: November 30, 2006Inventors: Goran Molin, Siv Ahrne, Bengt Jeppsson
-
Publication number: 20060257384Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.Type: ApplicationFiled: April 2, 2004Publication date: November 16, 2006Applicant: PROBI ABInventors: Göran Molin, Siv Ahrné, Bengt Jeppsson
-
Patent number: 6159465Abstract: The invention refers to the use of Lactobacillus plantarum 299v having a mannose-specific adhesin for the preparation of a pharmaceutical composition inhibiting the binding of pathogenic bacteria expressing mannose-specific adhesins to the epithelial cell surface. The strain of Lactobacillus plantiarum which can be used in the invention adheres to D-mannose-coated agarose beads. The invention also refers to the use of said strain for the preparation of a pharmaceutical composition to be used in prophylatic and/or curative treatment of bacterial translocation, gastroenteritis and other diseases caused by pathogenic bacteria expressing mannose-specific adhesins.Type: GrantFiled: September 23, 1997Date of Patent: December 12, 2000Assignee: Probi ABInventors: Ingegerd Adlerberth, Siv Ahrne, Bengt Jeppsson, Marie-Louise Johansson, Goran Molin, Agnes Wold
-
Patent number: 5591428Abstract: A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration. By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.Type: GrantFiled: June 6, 1995Date of Patent: January 7, 1997Assignee: Probi ABInventors: Stig Bengmark, Siv Ahrne, Goran Molin, Bengt Jeppson
-
Patent number: 5587314Abstract: A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration. By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.Type: GrantFiled: April 6, 1995Date of Patent: December 24, 1996Assignee: Probi ABInventors: Stig Bengmark, Siv Ahrne, Goran Molin, Bengt Jeppson
-
Patent number: 5474932Abstract: A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration.By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.Type: GrantFiled: April 16, 1993Date of Patent: December 12, 1995Assignee: Probi ABInventors: Stig Bengmark, Siv Ahrne, Goran Molin, Bengt Jeppson
-
Patent number: RE44400Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.Type: GrantFiled: April 2, 2004Date of Patent: July 30, 2013Assignee: Probi ABInventors: Göran Molin, Siv Ahrné, Bengt Jeppsson
-
Patent number: RE46718Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.Type: GrantFiled: June 5, 2013Date of Patent: February 20, 2018Assignee: Probi ABInventors: Goran Molin, Siv Ahrné, Bengt Jeppsson